Faron (LSE:FARN) Pharmaceuticals, the Finnish immuno-oncology company quoted on AIM and Nasdaq First North in Helsinki, has agreed with its convertible bondholder to push back a scheduled repayment, a move it said would limit near-term dilution for shareholders. The agreement, announced on 30 September 2026, comes as the company prepares to begin a mid-stage trial of its lead drug, bexmarilimab, in a form of blood cancer, following the completion of a large rights issue earlier in the year.

What the company does

Faron, which trades as Faron Pharmaceuticals Ltd (Oy in its Finnish form), is a clinical-stage biopharmaceutical company focused on immunotherapy. Its lead candidate, bexmarilimab, is designed to target a receptor on immune cells that tumours can exploit to evade the immune system. The drug is being developed mainly in higher-risk myelodysplastic syndrome (MDS), a group of bone marrow cancers, in combination with the standard therapy azacitidine, while investigator-led studies are exploring other blood cancers and solid tumours.

Latest developments

Under the September agreement with Heights Capital Management, Faron deferred €1.4m of principal due on 2 October 2026 across two bond tranches to their final maturities in 2028, and moved €161,000 of interest to 2 December 2026, with all other terms unchanged.

On the clinical side, the company reported a first overall survival data cut from its BEXMAB study on 27 July 2026. Among 21 previously untreated higher-risk MDS patients, median survival in the subgroup with biallelic TP53 mutations was 8.8 months, which Faron described as in line with historical data, while median survival had not yet been reached in the monoallelic TP53 and wildtype groups. Earlier data presented at the European Hematology Association congress showed a median complete remission duration of 16.1 months in treatment-naive patients. Faron plans to start the randomised, placebo-controlled Phase 2b BEXERA trial in the second half of 2026, aiming to enrol 90 participants at up to 35 sites in the US, Europe and the UK, and to select a dose for Phase 3.

In June 2026 the Nasdaq Helsinki disciplinary committee fined the company €30,000 over late disclosure of inside information and statements made in a 2024 media interview. Faron said the fine would not have a material impact.

Financial picture

In unaudited half-year results published on 26 August 2026, Faron reported a loss of €8.5m for the six months to 30 June, compared with €19.3m a year earlier, and an operating loss of €11.1m. Cash stood at €32.0m, boosted by a rights issue completed in April that raised gross proceeds of about €40.1m. Borrowings were about €17.8m and net assets about €11.6m. As a pre-revenue drug developer, Faron does not pay a dividend.

Sector and index context

Faron belongs to the cluster of loss-making biotechnology companies on the FTSE AIM All Share Index whose valuations depend heavily on clinical readouts and access to funding. Investor appetite for small-cap biotech has been selective, with companies often needing to raise capital at discounted prices.

Key risks

The company is reliant on a single lead asset and faces the usual risks of trial delays, disappointing efficacy or safety findings and regulatory setbacks. Its convertible bonds and the potential need for further equity raises create dilution risk, and any partnering deal remains uncertain.

What to watch next

Key milestones include the first patient dosed in the BEXERA trial, fuller BEXMAB survival data expected at a scientific meeting later in 2026, updates from investigator-initiated studies, progress in partnering discussions and the deferred bond interest payment due in December.